To estimate the impact of different modes of administration of SFN on meso CAR-T cells in vivo, we tested PD-1 expression and cytokine secretion of tumor- and spleen-infiltrating meso CAR-T cells from mice with different treatments (Fig. 5E–J). This evidence concerns the gene PDCD1 and neoplasm.